Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00492011 · ClinicalTrials.gov registry record · Phase 4

Efficacy of Ramelteon on Insomnia Symptoms Associated With Jet Lag in Healthy Adult Volunteers

A Phase 4 study of Circadian Dysregulation, sponsored by Takeda.

Completed
Registry status
Phase 4
Development phase
110
Enrollment target
4
Study locations

NCT00492011: Completed Phase 4 study of Circadian Dysregulation, sponsored by Takeda.

NCT00492011 is a Phase 4 study of Circadian Dysregulation that has completed, run by Takeda. The registered enrollment target is 110 participants, above the 60-participant average among 10 other Circadian Dysregulation trials with a reported enrollment target (83% higher). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00492011, a Phase 4 study of Circadian Dysregulation, has completed, sponsored by Takeda.

COMPLETED
Registry status
Phase 4
Development phase
110 participants
Enrollment target
4
Study locations

Study Summary

The purpose of this study to determine the degree to which ramelteon, once daily (QD), can reduce the insomnia symptoms associated with rapid, eastward travel across 5 time zones.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Ramelteon

Study Locations (4)

Florida

  • - Miami
  • - Pembroke Pines

Hawaii

  • - Honolulu

New York

  • - New York

Trial Details

FieldValue
Enrollment Target 110 participants
Start Date 2007-02
Est. Completion 2007-08
Phase Phase 4
Takeda

408 total trials

What the finished NCT00492011 record still lists

NCT00492011 is an interventional study that assigns participants to a tested intervention. The registered 110 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 10 other Circadian Dysregulation trials with a reported enrollment target (83% higher).

The record links to 1 condition, with Circadian Dysregulation appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00492011 reports a single indexed study location in Florida, Hawaii, New York.

Frequently Asked Questions

What is clinical trial NCT00492011 about?

NCT00492011 is a clinical study titled "Efficacy of Ramelteon on Insomnia Symptoms Associated With Jet Lag in Healthy Adult Volunteers". The purpose of this study to determine the degree to which ramelteon, once daily (QD), can reduce the insomnia symptoms associated with rapid, eastward travel across 5 time zones.

What is the current status of trial NCT00492011?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 110 participants. The study started on 2007-02. Estimated completion is 2007-08.

What conditions does trial NCT00492011 study?

This clinical trial studies the following conditions: Circadian Dysregulation.

What interventions are being tested in trial NCT00492011?

The interventions under investigation include: Placebo (DRUG), Ramelteon (DRUG).

Who is sponsoring clinical trial NCT00492011?

This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00492011 being conducted?

This trial has 4 study locations across Florida, Hawaii, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Circadian Dysregulation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00492011's enrollment target sits among peer trials

110 4th of 10 higher than 7 of 10 other Circadian Dysregulation trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Circadian Dysregulation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01530373 · 110 participants · Phase 2

    Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients

  • NCT02379377 · 110 participants · Phase 1

    18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant

  • NCT02411773 · 110 participants · Phase 1

    Sympatholysis in Chronic Kidney Disease

  • NCT03190941 · 110 participants · Phase 1

    Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00492011, the US trial registry maintained by the National Library of Medicine. NCT00492011 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.